PL EN


Preferences help
enabled [disable] Abstract
Number of results
2008 | 56 | 2 | 115-122
Article title

Role of response gene to complement 32 in disease

Title variants
Languages of publication
EN
Abstracts
EN
The role of response gene to complement (RGC)-32 as a cell cycle regulator has been attributed to its ability to activate cdc2 kinases and to induce S-phase entry and mitosis. However, recent studies revealed novel functions for RGC-32 in diverse processes such as cellular differentiation, inflammation, and fibrosis. Besides responding to C5b-9 stimulation, RGC-32 expression is also induced by growth factors, hormones, and cytokines. Transforming growth factor ? activates RGC-32 through Smad and RhoA signaling, thus initiating smooth muscle cell differentiation. Accumulating evidence has drawn attention to the deregulated expression of RGC-32 in human malignancies, hyper-immunoglobulin E syndrome, and fibrosis. RCG-32 expression is up-regulated in cutaneous T cell lymphoma and colon, ovarian, and breast cancer, but down-regulated in invasive prostate cancer, multiple myeloma, and drug-resistant glioblastoma. A better understanding of the mechanism by which RGC-32 contributes to the pathogenesis of these diseases will provide new insights into its therapeutic potential. In this review we provide an overview of this field and discuss the most recent research on RGC-32.
Keywords
Publisher

Year
Volume
56
Issue
2
Pages
115-122
Physical description
Contributors
author
author
author
author
author
author
author
author
References
Document Type
REVIEW
Publication order reference
Horea Rus, M.D. Ph.D., Department of Neurology, University of Maryland, School of Medicine, 655 W. Baltimore St, BRB 12-033, Baltimore, MD 21201, USA
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-06813b39-d345-386e-98b8-9760cc4ea7b2
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.